GENEART AG Receives Major Contract from the Wellcome Trust Sanger Institute

Regensburg, November 26, 2008 - GENEART AG, world market leader for gene synthesis and specialist in Synthetic Biology, announces the closing of a major contract with the Wellcome Trust Sanger Institute, UK. GENEART will synthesize up to 600 tailor-made genes for the Wellcome Trust Sanger Institute's research program under this contract. The genes will be used to identify mechanisms involved in defined genetic and infectious disease. The terms of the agreement were not disclosed.

Back to news